AnaptysBio (NASDAQ:ANAB) moved to dismantle a key legal pillar of GSK’s (NYSE:GSK) defense in the Delaware Chancery Court on Thursday, filing a motion to dismiss claims that the biotech "repudiated" its lucrative royalty agreement for the blockbuster-intent cancer drug Jemperli.
Johnson & Johnson (NYSE:JNJ) became the latest pharmaceutical titan to bow to White House pressure, announcing a voluntary agreement to lower prescription drug costs in exchange for an exemption from the administration’s aggressive new import tariffs.
The US House approved a bill to extend healthcare subsidies, though its future in the Senate remains unclear.
CorMedix (NASDAQ:CRMD) reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, alongside initial fiscal 2026 guidance and program updates.
Menlo Park, California-based Personalis (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, reported unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.
Acrivon Therapeutics (NASDAQ:ACRV) unveiled promising interim data from its lead oncology program on Thursday, demonstrating that its biomarker-driven approach can achieve significant results in patients with hard-to-treat serous endometrial cancer.
The company’s lead candidate, ACR-368, a selective CHK1/2 inhibitor, showed a 67% confirmed objective response rate (cORR) in a subset of patients identified by Acrivon’s proprietary "OncoSignature" biomarker.
Viking Therapeutics (NASDAQ:VKTX) finished enrolling patients in a clinical trial designed to test how different dosing schedules of its experimental obesity drug can help people keep weight off, a key step in its bid to compete with established giants in the metabolic space.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive interim data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI in patients with eosinophilic esophagitis.
Watertown, Massachusetts-based Acrivon Therapeutics (NASDAQ:ACRV) provided an interim clinical update across its precision oncology pipeline, highlighted by promising response rates for its lead candidate ACR-368 in an ongoing Phase 2b trial.
Invivyd (NASDAQ:IVVD) reported preliminary fourth-quarter net product revenue of $17.2 million for its COVID-19 antibody, PEMGARDA.
The figure marks a 25% increase over the same period last year and a 31% sequential jump from the third quarter.
NervGen Pharma Corp. (NASDAQ:NGEN) officially began trading on the Nasdaq Stock Market on January 8, marking a transition into a late-stage biopharmaceutical player.
Organon (NYSE:OGN) has entered a strategic agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid), a first-in-class treatment for high cholesterol, across France, Denmark, Iceland, Sweden, Finland, and Norway.
